What recent performance says about Select Medical Holdings
Select Medical Holdings (SEM) has drawn attention after recent trading, with the stock closing at US$16.48 and posting modest gains over the past week, month, and past 3 months, while year to date returns remain in positive territory.
See our latest analysis for Select Medical Holdings.
Recent share price returns have been steady rather than sharp. The year to date share price return of 11.2% sits alongside a 1 year total shareholder return of 10.36%, while the 5 year total shareholder return shows a decline of 16.07%. This hints that current momentum is building from a softer long term base.
If this kind of moderate recovery has you thinking about other opportunities in healthcare, it could be a good moment to widen your search with 31 healthcare AI stocks
With SEM trading close to a US$16.50 analyst price target and its own intrinsic value estimate implying a premium, the real question is whether the stock is now fully priced or if markets are overlooking the potential for future growth.
Most Popular Narrative: 10% Undervalued
With Select Medical Holdings last closing at $16.48 against a narrative fair value of $16.50, the current setup frames a small discount as analysts focus on how 2026 guidance and capital structure shape longer term outcomes.
Continual regulatory pressures, particularly ongoing reductions to Medicare reimbursement rates and the recent, unexpected 20% transmittal rule impacting LTACHs, are suppressing revenue growth and compressing margins, with leadership acknowledging these headwinds are likely to persist as part of their long term financial guidance.
Want to see why this fair value still comes out ahead of today’s price? The narrative leans on measured revenue growth, firmer margins, and a lower earnings multiple to tie it all together.
Result: Fair Value of $16.50 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, investors still have to weigh regulatory pressure on Medicare reimbursement and the company’s sizable US$1.9b debt load, which could constrain flexibility if conditions tighten.
Find out about the key risks to this Select Medical Holdings narrative.
Another Take On Value: Cash Flows Paint A Tougher Picture
While earnings based metrics suggest SEM is on the cheaper side, the SWS DCF model tells a different story. On that view, SEM at $16.48 sits above an estimated future cash flow value of $12.82, which points to an overvalued stock and raises the question of how reliable near term earnings really are.
For investors who want to see how this cash flow view is built up line by line, Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Select Medical Holdings for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Seeing mixed signals on value and risk so far? Examine the numbers yourself and decide where you stand on Select Medical Holdings with 4 key rewards and 2 important warning signs
Looking for more investment ideas?
If SEM has sharpened your focus, do not stop there. Broaden your watchlist with fresh ideas that could better match your goals and risk comfort.
- Target stability first by scanning 65 resilient stocks with low risk scores that keep volatility in check while still offering room for thoughtful growth.
- Hunt for value by reviewing 51 high quality undervalued stocks that combine solid fundamentals with prices that may not fully reflect their underlying quality.
- Spot potential early by checking the screener containing 21 high quality undiscovered gems before they attract wider attention and become crowded trades.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com